Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodies

Zane Kraft, Nina R. Derby, Ruth A. McCaffrey, Rachel Niec, Wendy M. Blay, Nancy Haigwood, Eirini Moysi, Cheryl J. Saunders, Terri Wrin, Christos J. Petropoulos, M. Juliana McElrath, Leonidas Stamatatos

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

The development of anti-human immunodeficiency virus (anti-HIV) neutralizing antibodies and the evolution of the viral envelope glycoprotein were monitored in rhesus macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV), SHIVSF162P4. Homologous neutralizing antibodies developed within the first month of infection in the majority of animals, and their titers were independent of the extent and duration of viral replication during chronic infection. The appearance of homologous neutralizing antibody responses was preceded by the appearance of amino acid changes in specific variable and conserved regions of gp120. Amino acid changes first appeared in the V1, V2, C2, and V3 regions and subsequently in the C3, V4, and V5 regions. Heterologous neutralizing antibody responses developed over time only in animals with sustained plasma viremia. Within 2 years postinfection the breadth of these responses was as broad as that observed in certain patients infected with HIV type 1 (HIV-1) for over a decade. Despite the development of broad anti-HIV-1 neutralizing antibody responses, viral replication persisted in these animals due to viral escape. Our studies indicate that cross-reactive neutralizing antibodies are elicited in a subset of SHIVSF162P4 infected macaques and that their development requires continuous viral replication for extended periods of time. More importantly, their late appearance does not prevent progression to disease. The availability of an animal model where cross-reactive anti-HIV neutralizing antibodies are developed may facilitate the identification of virologic and immunologic factors conducive to the development of such antibodies.

Original languageEnglish (US)
Pages (from-to)6402-6411
Number of pages10
JournalJournal of Virology
Volume81
Issue number12
DOIs
StatePublished - Jun 2007
Externally publishedYes

Fingerprint

Simian Immunodeficiency Virus
Human immunodeficiency virus
Macaca
Neutralizing Antibodies
neutralizing antibodies
tropics
HIV
virus replication
Antibody Formation
HIV-1
immunologic factors
Heterophile Antibodies
Amino Acids
animals
amino acids
Viremia
viremia
Immunologic Factors
Human immunodeficiency virus 1
Macaca mulatta

ASJC Scopus subject areas

  • Immunology

Cite this

Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodies. / Kraft, Zane; Derby, Nina R.; McCaffrey, Ruth A.; Niec, Rachel; Blay, Wendy M.; Haigwood, Nancy; Moysi, Eirini; Saunders, Cheryl J.; Wrin, Terri; Petropoulos, Christos J.; McElrath, M. Juliana; Stamatatos, Leonidas.

In: Journal of Virology, Vol. 81, No. 12, 06.2007, p. 6402-6411.

Research output: Contribution to journalArticle

Kraft, Z, Derby, NR, McCaffrey, RA, Niec, R, Blay, WM, Haigwood, N, Moysi, E, Saunders, CJ, Wrin, T, Petropoulos, CJ, McElrath, MJ & Stamatatos, L 2007, 'Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodies', Journal of Virology, vol. 81, no. 12, pp. 6402-6411. https://doi.org/10.1128/JVI.00424-07
Kraft, Zane ; Derby, Nina R. ; McCaffrey, Ruth A. ; Niec, Rachel ; Blay, Wendy M. ; Haigwood, Nancy ; Moysi, Eirini ; Saunders, Cheryl J. ; Wrin, Terri ; Petropoulos, Christos J. ; McElrath, M. Juliana ; Stamatatos, Leonidas. / Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodies. In: Journal of Virology. 2007 ; Vol. 81, No. 12. pp. 6402-6411.
@article{5739f48fdbfe4883a7d1f201be3172fa,
title = "Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodies",
abstract = "The development of anti-human immunodeficiency virus (anti-HIV) neutralizing antibodies and the evolution of the viral envelope glycoprotein were monitored in rhesus macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV), SHIVSF162P4. Homologous neutralizing antibodies developed within the first month of infection in the majority of animals, and their titers were independent of the extent and duration of viral replication during chronic infection. The appearance of homologous neutralizing antibody responses was preceded by the appearance of amino acid changes in specific variable and conserved regions of gp120. Amino acid changes first appeared in the V1, V2, C2, and V3 regions and subsequently in the C3, V4, and V5 regions. Heterologous neutralizing antibody responses developed over time only in animals with sustained plasma viremia. Within 2 years postinfection the breadth of these responses was as broad as that observed in certain patients infected with HIV type 1 (HIV-1) for over a decade. Despite the development of broad anti-HIV-1 neutralizing antibody responses, viral replication persisted in these animals due to viral escape. Our studies indicate that cross-reactive neutralizing antibodies are elicited in a subset of SHIVSF162P4 infected macaques and that their development requires continuous viral replication for extended periods of time. More importantly, their late appearance does not prevent progression to disease. The availability of an animal model where cross-reactive anti-HIV neutralizing antibodies are developed may facilitate the identification of virologic and immunologic factors conducive to the development of such antibodies.",
author = "Zane Kraft and Derby, {Nina R.} and McCaffrey, {Ruth A.} and Rachel Niec and Blay, {Wendy M.} and Nancy Haigwood and Eirini Moysi and Saunders, {Cheryl J.} and Terri Wrin and Petropoulos, {Christos J.} and McElrath, {M. Juliana} and Leonidas Stamatatos",
year = "2007",
month = "6",
doi = "10.1128/JVI.00424-07",
language = "English (US)",
volume = "81",
pages = "6402--6411",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "12",

}

TY - JOUR

T1 - Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodies

AU - Kraft, Zane

AU - Derby, Nina R.

AU - McCaffrey, Ruth A.

AU - Niec, Rachel

AU - Blay, Wendy M.

AU - Haigwood, Nancy

AU - Moysi, Eirini

AU - Saunders, Cheryl J.

AU - Wrin, Terri

AU - Petropoulos, Christos J.

AU - McElrath, M. Juliana

AU - Stamatatos, Leonidas

PY - 2007/6

Y1 - 2007/6

N2 - The development of anti-human immunodeficiency virus (anti-HIV) neutralizing antibodies and the evolution of the viral envelope glycoprotein were monitored in rhesus macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV), SHIVSF162P4. Homologous neutralizing antibodies developed within the first month of infection in the majority of animals, and their titers were independent of the extent and duration of viral replication during chronic infection. The appearance of homologous neutralizing antibody responses was preceded by the appearance of amino acid changes in specific variable and conserved regions of gp120. Amino acid changes first appeared in the V1, V2, C2, and V3 regions and subsequently in the C3, V4, and V5 regions. Heterologous neutralizing antibody responses developed over time only in animals with sustained plasma viremia. Within 2 years postinfection the breadth of these responses was as broad as that observed in certain patients infected with HIV type 1 (HIV-1) for over a decade. Despite the development of broad anti-HIV-1 neutralizing antibody responses, viral replication persisted in these animals due to viral escape. Our studies indicate that cross-reactive neutralizing antibodies are elicited in a subset of SHIVSF162P4 infected macaques and that their development requires continuous viral replication for extended periods of time. More importantly, their late appearance does not prevent progression to disease. The availability of an animal model where cross-reactive anti-HIV neutralizing antibodies are developed may facilitate the identification of virologic and immunologic factors conducive to the development of such antibodies.

AB - The development of anti-human immunodeficiency virus (anti-HIV) neutralizing antibodies and the evolution of the viral envelope glycoprotein were monitored in rhesus macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV), SHIVSF162P4. Homologous neutralizing antibodies developed within the first month of infection in the majority of animals, and their titers were independent of the extent and duration of viral replication during chronic infection. The appearance of homologous neutralizing antibody responses was preceded by the appearance of amino acid changes in specific variable and conserved regions of gp120. Amino acid changes first appeared in the V1, V2, C2, and V3 regions and subsequently in the C3, V4, and V5 regions. Heterologous neutralizing antibody responses developed over time only in animals with sustained plasma viremia. Within 2 years postinfection the breadth of these responses was as broad as that observed in certain patients infected with HIV type 1 (HIV-1) for over a decade. Despite the development of broad anti-HIV-1 neutralizing antibody responses, viral replication persisted in these animals due to viral escape. Our studies indicate that cross-reactive neutralizing antibodies are elicited in a subset of SHIVSF162P4 infected macaques and that their development requires continuous viral replication for extended periods of time. More importantly, their late appearance does not prevent progression to disease. The availability of an animal model where cross-reactive anti-HIV neutralizing antibodies are developed may facilitate the identification of virologic and immunologic factors conducive to the development of such antibodies.

UR - http://www.scopus.com/inward/record.url?scp=34249952292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249952292&partnerID=8YFLogxK

U2 - 10.1128/JVI.00424-07

DO - 10.1128/JVI.00424-07

M3 - Article

C2 - 17392364

AN - SCOPUS:34249952292

VL - 81

SP - 6402

EP - 6411

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 12

ER -